Hsbc Holdings PLC lowered its stake in Enovis Corporation (NYSE:ENOV – Free Report) by 19.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 280,716 shares of the company’s stock after selling 67,115 shares during the period. Hsbc Holdings PLC’s holdings in Enovis were worth $7,575,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Arax Advisory Partners bought a new stake in shares of Enovis during the fourth quarter worth $29,000. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the period. GAMMA Investing LLC lifted its position in Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after acquiring an additional 1,446 shares in the last quarter. Danske Bank A S bought a new stake in Enovis in the 3rd quarter valued at $64,000. Finally, iSAM Funds UK Ltd bought a new stake in Enovis in the 3rd quarter valued at $80,000. Institutional investors and hedge funds own 98.45% of the company’s stock.
Enovis Stock Performance
Shares of ENOV opened at $23.64 on Thursday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -1.19 and a beta of 1.39. Enovis Corporation has a 12 month low of $19.14 and a 12 month high of $36.82. The firm has a fifty day simple moving average of $23.30 and a 200 day simple moving average of $23.80. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on ENOV shares. Wells Fargo & Company lowered their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Monday. William Blair started coverage on Enovis in a report on Friday, April 17th. They set an “outperform” rating for the company. Finally, Zacks Research lowered Enovis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Enovis presently has an average rating of “Moderate Buy” and an average price target of $41.71.
Get Our Latest Analysis on Enovis
Insider Buying and Selling at Enovis
In related news, insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders bought 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by company insiders.
About Enovis
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Featured Articles
- Five stocks we like better than Enovis
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV – Free Report).
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
